Larimar Proposes Another Mid-Stage Study For Rare Neuromuscular Disorder

  • Larimar Therapeutics Inc LRMR received meeting minutes from the FDA following a recent Type C Meeting.
  • The company plans to submit a complete response to the CTI-1601 clinical hold in Q3.
  • In conjunction with the complete response, Larimar is proposing as CTI-1601's next trial a Phase 2, four-week dose exploration study in Friedreich's Ataxia starting at the lower dose levels tested in the company's Phase 1 multiple-ascending dose trial. 
  • This study will provide additional data on safety & tolerability and whether lower doses for longer periods can increase frataxin levels while maintaining acceptable exposures.
  • Related: FDA Asks For Additional Data To Resolve Clinical Hold On Larimar's Friedreich's Ataxia Program.
  • Data from Phase 1 trials showed that 50 or 100 mg of CTI-1601, administered daily for at least seven days, resulted in frataxin levels in peripheral tissues (buccal cells). 
  • Cohort 1 of the MAD trial evaluated a 25 mg dose and explored a daily dosing regimen for only four days.
  • Larimar ended the June quarter with a cash balance of $54.9 million, which provides a projected cash runway through Q3 of 2023.
  • Price Action: LRMR shares are up 14.64% at $2.27 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!